SLN.L Regulatory News (SLN)

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Silence Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Disclosure due to increased aggregation of holdings (See 'Box 13 - Additional Information' below)

X

3. Full name of person(s) subject to thenotification obligation: iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

26 June 2016

6. Date on which issuer notified:

29 June 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

22,23,24%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B9GTXM62

15,269,014

15,269,014

17,458,481

17,458,481

24.94%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

17,458,481

24.94%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The above undertakings are all controlled by Richard Griffiths

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

Sarossa Plc has now become a controlled undertaking of Richard Griffiths for DTR rule purposes. As such Sarossa Plc's shareholding in Silence Therapeutics Plc, as shown in box 9, is now aggregated into 'Richard Griffiths and controlled undertakings' disclosures. The movement in shares in this disclosure is due to that aggregation and no further shares in Silence Therapeutics Plc were acquired by Richard Griffiths, his controlled undertakings or Sarossa Plc as part of this disclosure.

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+ 44 1534 719 761